Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C

    Hepatitis C virus (HCV) is chiefly transmitted by blood-to-blood contact. When the blood of a person with hepatitis C enters the bloodstream of another person,...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1
  • Hepatitis C virus treatment

    The current preferred treatment regimen for HCV infection is a combination of peginterferon alfa (given by injection) plus ribavirin (given orally). Interferons are human proteins that...

    From: HIV treatments directory

    Information level Level 4
  • Hepatitis C treatment

    Effective treatments are available for hepatitis C. This field is evolving rapidly and standards of care are changing. The newest drugs can cure most people with hepatitis...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    The old standard of care for hepatitis C treatment for all HCV genotypes was pegylated interferon and ribavirin. Interferon works by stimulating immune system activity against HCV. There...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • KEI Europe asks Romanian government to issue compulsory licences on hepatitis C medicines

    For a country with a gross national income (GNI) per capita of $9,060, roughly one-quarter of the overall GNI per capita across the EU, the medicines are simply too costly to be within reach of patients in need, and put strains on the government's ability to provide reimbursements.

    23 March 2015 | Knowledge Ecology International
  • Indian generic companies should reject Gilead’s controversial hepatitis C ‘Anti-Diversion’ programme

    Ahead of a meeting in Jaipur, India next week between US pharmaceutical company Gilead Sciences and several Indian companies which have entered into an agreement with Gilead to produce hepatitis C drugs, Médecins Sans Frontières/Doctors Without Borders (MSF) urged the generic companies to reject a highly-controversial programme that could compromise people’s treatment and confidentiality.

    19 March 2015 | MSF
  • Gilead to require proof of citizenship to buy Sovaldi in poor countries

    Médecins Sans Frontières/Doctors Without Borders (MSF) is urging Gilead to drop some of the provisions. If Gilead won't, MSF suggests that generic drugmakers ignore some of the requirements, like demanding that patients provide proof of citizenship to fill a prescription.

    19 March 2015 | Fierce Pharma
  • Bristol-Myers Squibb Co. Is Back in the Hepatitis C Race

    Bristol-Myers Squibb took an intriguing approach to developing its hepatitis C drug, daclatasvir. Rather than focus its trials on the United States, the globe's biggest market for spending on medicine, it concentrated trials on Japan. That move allowed daclatasvir to carve out an early lead in Japan, but it also left investors wondering what the company's strategy for the drug in the United States would be -- particularly after the FDA balked at an initial application to approve the drug last fall. This week, Bristol-Myers shed some light on its strategy by announcing that it's resubmitting daclatasvir for approval in the U.S. as an adjunct treatment to be used alongside Gilead Sciences' (NASDAQ: GILD ) top-selling HCV drug Sovaldi in genotype 3 patients.

    18 March 2015 | Motley Fool
  • Hepatitis C Drugs Will 'Strain Budgets': Study

    New hepatitis C drugs promise cure rates above 90 percent, but could prove to be budget-busters for public and private health insurers, a new analysis finds.

    17 March 2015 | WebMD
  • Gilead's hepatitis C drugs largely cost-effective in US - study

    New hepatitis C drugs that shorten treatment times are largely cost-effective despite their hefty U.S. price tags, according to two new analyses.

    17 March 2015 | Reuters
  • Hepatitis C pills drive surge in U.S. drug costs: report

    Highly effective but expensive new pills to treat hepatitis C drove a 13.1 percent increase U.S. prescription drug spending in 2014, the fastest rate of increase in more than a decade, according to Express Scripts.

    12 March 2015 | Reuters
  • Here Is Why Gilead Sciences, Inc. Is Still Doing Better Than AbbVie Inc

    Based on the prescription data released by Symphony Health, the latest Bloomberg Intelligence (BI) analysis suggests that 95% of hepatitis C patients in the US are being administered with Gilead’s drugs, Harvoni and Sovaldi. On the other hand, AbbVie’s competing drug, Viekira Pak is only covering the remaining 4%.

    10 March 2015 | Bidness
  • $10 Copy of Gilead Blockbuster Sovaldi Appears in Bangladesh

    Incepta Pharmaceuticals Ltd. doesn’t have a license from Gilead and its version was launched last month, said Managing Director Abdul Muktadir. The company also aims to sell the drug overseas, including to parts of Southeast Asia and Africa.

    09 March 2015 | Bloomberg
  • EECA CAB positions in regards to Janssen, BMS, Gilead and ViiV policy

    EECA CAB (Community Advisory Board in Eastern Europe and Central Asia) has published its positions in regards to Janssen, BMS, ViiV and Gilead policy. The positions were developed on the results of the meetings with the companies during last year.

    09 March 2015 | EATG
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.